15,15-dialkyl-substituted derivatives of estradiol

ABSTRACT

New 15,15-dialkyl-substituted derivatives of the estradiol of general formula I ##STR1## in which R 1  and R 2 , independently of one another, are each a hydrogen atom or a straight-chain alkanoyl group with 1 to 10 carbon atoms, a branched-chain alkanoyl group with 3-10 carbon atoms, an alkanoyl group of 3-10 carbon atoms containing a cycloaliphatic structure of 3-6 carbon ring atoms or a benzoyl group, and 
     R 3  and R 4 , independently of one another, are each a straight-chain alkyl group with 1 to 10 carbon atoms or a branched-chain alkyl group with 3 to 10 carbon atoms, 
     are described, a process for their production and initial products for this process. The new compounds have--also after oral administration--high estrogenic effectiveness and are suitable for the production of pharmaceutical agents.

This is a division of application Ser. No. 08/284,786 filed Aug. 2,1994, now U.S. Pat. No. 5,587,496.

This invention relates to the new 15,15-dialkyl-substituted derivativesof estradiol of general formula I ##STR2## in which

R¹ and R², independently of one another, are each a hydrogen atom, astraight-chain alkanoyl group with 1 to 10 carbon atoms, abranched-chain alkanoyl group with 3 to 10 carbon atoms, an alkanoylgroup of 3-10 carbon atoms containing a cycloaliphatic structure of 3-6carbon ring atoms, or a benzoyl group, and

R³ and R⁴, independently of one another, are each a straight-chain alkylgroup with 1 to 10 carbon atoms or a branched-chain alkyl group with 3to 10 carbon atoms.

Radicals R¹ and R² can be identical or different.

Radicals R¹ and/or R² preferably stand for a hydrogen atom.

As acyl groups R¹ and R², radicals from organic carboxylic acids with 1to 10 carbon atoms are suitable. Such radicals are derived fromaliphatic, cycloaliphatic, aliphatic-cycloaliphatic and aromaticmonocarboxylic acids. The number of carbon atoms in the ring structurescan vary from 3 to 6. As radicals R¹ and R², the acyl groups of aceticacid, propionic acid, butyric acid, isobutyric acid, pivalic acid,caproic acid, heptanoic acid, caprylic acid, pelargonic acid, decanoicacid, 3-cyclopentylpropionic acid and benzoic acid are preferred.

For radicals R³ and R⁴, methyl, ethyl, propyl, isopropyl, butyl,isobutyl and tert-butyl groups are preferred. But, the higher,homologous straight-chain and branched-chain alkyl groups up to a decylradical are also suitable.

The R³ and R⁴ radicals can be identical or different.

In particular, carbon atom 15 is preferably substituted by two methylgroups. As an especially preferred compound according to the invention,15,15-dimethyl-estra-1,3,5(10)-triene-3,17β-diol can be mentioned.

The compounds of general formula I according to the invention exhibit astrong affinity to the estrogen receptor and, in particular, also havehigh estrogenic effectiveness after oral administration.

As compounds with high estrogenic effectiveness, for example, thenatural estrogens estradiol and estriol (E. Schroder, C. Rufer and R.Schmiechen, Pharmazeutische Chemie [Pharmaceutical Chemistry], 1982,Georg Thieme Verlag, Stuttgart-New York, p. 568 ff) are known. But, theyare metabolically not stable and after oral administration, arecatabolized by oxidation of the 17-hydroxy group to the corresponding,less effective estrone derivative. Based on this quick metabolicinactivation, they are hardly suitable for oral use.

By introducing, for example, an ethinyl group on the 17-C atom(ethinylestradiol, loc. cit., p. 574), the oxidation of the 17-hydroxygroup can be prevented, and the corresponding derivatives consequentlyhave at their disposal high estrogenic effectiveness after peroraladministration.

Only recently has it been possible to obtain estrogenic compounds withhigh peroral effectiveness, not by variations of the substituents on thesteroid skeleton, but by modification of the steroid skeleton itself.The bridging of the 14- and 17-carbon atoms of the estradiol with anetheno- or ethano bridge thus blocks the oxidation of the 17β-hydroxygroup (J. Chem. Commun., 1986, 451-453 or International PatentApplication PCT/DE 87/00361).

Derivatives of the estradiol, which carry a 14α,15α-methylene group,also represent compounds with high estrogenic effectiveness after oraladministration (U.S. Pat. No. 4,231,946).

After oral administration, the estrogenic action of the compounds ofgeneral formula I according to the invention is comparable with that ofthe standard 17α-ethinylestradiol. In the compounds according to theinvention, the attack of the steroid-17β-dehydrogenase is blocked by theintroduction of two alkyl groups in C-15-position and thus impedes themetabolic oxidation of the 17-hydroxy group despite the presence of ahydrogen atom on the 17-C atom.

BRIEF DESCRIPTION OF THE DRAWING

Various other objects, features and attendant advantages of the presentinvention will be more fully appreciated as the same becomes betterunderstood when considered in conjunction with the accompanying drawingwherein:

FIG. 1 is a graph demonstrating the stability of estradiol and15,15-dimethyl-estra-1,3,5(10)-triene-3,17β-diol with respect to17β-hydroxysteroid dehydrogenase.

DETAILED DESCRIPTION

To determine the stability of estradiol (A) itself as well as of acompound according to the invention, i.e.,15,15-dimethyl-estra-1,3,5(10)-triene-3,17β-diol (B), against17β-hydroxysteroid dehydrogenase from human placenta, the testsubstances are incubated with placenta microsomes in the presence ofNADP (nicotinamide-adenine-dinucleotide phosphate; 0.5 mmol).

The steroids (initial substrate and product) are extracted and separatedby HPLC. For evaluation, the quotients are formed from theelectronically integrated peak areas of the corresponding reactionproduct (namely the assumed 17-keto compound) and the initial substanceand plotted against the incubation time (FIG. 1). While estradiol (A) isconverted to the estrone by the 17β-hydroxy-steroid dehydrogenase to aconsiderable extent, the compound according to the invention15,15-dimethyl-estra-1,3,5(10)-triene-3,17β-diol (B) represents an onlymoderate substrate for the 17β-hydroxysteroid dehydrogenase.

This can explain the oral effectiveness of the newly describedsubstances.

The estrogenic effectiveness of the compounds according to the inventioncan be shown by the results of the estrogen receptor binding test. Inthis known in vitro test, tissue from rat uteri is prepared andradioactively-labeled ³ H-estradiol is used as reference substance. Thecompound according to the invention15,15-dimethyl-estra-1,3,5(10)-triene-3,17β-diol accordingly has acompetition factor K of 1.5.

The invention also relates to the use of the compounds of generalformula I for the production of pharmaceutical agents.

The compounds according to the invention can be formulated and used inthe same way as ethinylestradiol, which is the most used estrogen. Theyare processed to the usual forms of pharmaceutical agents with theadditives, vehicles and/or flavoring substances usual in galenicalpharmacy according to methods known in the art. For oral administration,especially tablets, coated tablets, capsules, pills, suspensions orsolutions are suitable. For parenteral administration, especially oilysolutions, such as, for example, sesame oil or castor oil solutions, aresuitable, which can optionally contain in addition a diluent, such as,for example, benzyl benzoate or benzyl alcohol.

The active ingredient concentration in the pharmaceutical compositionsis a function of the form of administration and the field ofapplication. Thus, for example, capsules or tablets for treatingestrogen deficiency symptoms can contain about 0.001-0.05 mg of activeingredient, oily solutions for intramuscular injection can contain about0.01-0.1 mg of active ingredient per 1 ml and vaginal ointments cancontain about 0.1-10 mg per 100 ml of ointment. For contraception in thefemale, the estrogens according to the invention can be used incombination with the gestagens typically used in hormonal contraceptivesor proposed for use in such preparations, e.g., progesterone,medroxyprogesterone acetate, gestonorone caproate, chlormadinoneacetate, lynestrenol, hydroxyprogesterone caproate, norethindrone andits esters (e.g., acetate), norgestrel, laevonorgestrel, cyproteroneacetate, desogestrel, norgestimate, dihydrospirorenone and gestodene.Tablets or coated tablets for daily intake of a tablet or a coatedtablet preferably contain about 0.003-0.05 mg of the estrogen accordingto the invention and preferably about 0.05-0.5 mg of a gestagen.

The compounds according to the invention can be used in the case ofestrogen deficiency symptoms of the female, such as, for example,amenorrhea, dysmenorrhea, sterility, endometritis, colpitis andclimacteric symptoms (hormone replacement therapy) and for theprevention of osteoporosis. Further, the compounds can be used asestrogenic components in hormonal contraceptives (single-phase andmulti-phase and multi-stage preparations). Furthermore, they aresuitable in connection with other active ingredients for use inhormone-carrying intrauterine pessaries, implantable active ingredientvehicles as well as in transdermal administration systems. Possiblefields of use of the compounds of general formula I according to theinvention in such transdermal systems are female birth control andhormone replacement therapy (HRT).

The increased fat solubility, in comparison to estradiol and17α-ethinylestradiol, based on the lipophilic alkyl groups in15-position, makes the compounds according to the invention especiallysuitable for use in such depot formulations.

The new compounds of general formula I ##STR3## in which

R¹ and R², independently of one another, are each a hydrogen atom, astraight-chain alkanoyl group with 1 to 10 carbon atoms, abranched-chain alkanoyl group with 3 to 10 carbon atoms, an alkanoylgroup of 3-10 carbon atoms containing a cycloaliphatic structure of 3-6carbon ring atoms, or a benzoyl group, and

R³ and R⁴, independently of one another, are each a straight-chain alkylgroup with 1 to 10 carbon atoms or a branched-chain alkyl group with 3to 10 carbon atoms, are produced, by a process wherein the 3-alkyletherof a compound of general formula II ##STR4## in which

R^(1') is a straight-chain alkyl group with 1 to 10 carbon atoms or abranched-chain alkyl group of 3 to 10 carbon atoms, and

R³ and R⁴ have the meaning indicated in formula I, is cleaved accordingto standard processes. Optionally the 3-hydroxy group is esterified andthen, subsequently, the 17-hydroxy group is optionally esterified.Alternatively, the 3- and 17-hydroxy groups are optionallysimultaneously esterified and optionally the resultant 3,17-diacyloxy isselectively saponified to a 3-hydroxy-17-acyloxy compound.

Alkyl groups for R^(1') with up to 10 carbon atoms are, for example,methyl, ethyl, propyl, isopropyl, butyl, isobutyl or tert-butyl or elsea higher homologue of the above-mentioned groups. A methyl group ispreferred.

The cleavage of the 3-alkylether is performed according to conventionalmethods of steroid ether cleavage. Thus, the 3-alkyl ether cleavage canbe performed in the boiling heat, for example, with a Lewis acid in aninert solvent. As Lewis acids, for example, boron trifluoride etherateor diisobutylaluminum hydride (DIBAH) are suitable. As solvents,benzene, toluene, tetrahydrofuran, dioxane, i.a., are suitable.

For the subsequent optional esterification of the phenolic and tertiaryhydroxy group, the known processes used for esterification in steroidchemistry can be employed.

The esterification is performed, for example, by reaction with acorresponding carboxylic acid halide (chloride or bromide) or carboxylicacid anhydride (carbon number depending on the ultimately desired R¹and/or R²) in the presence of a base such as, for example,4-dimethylaminopyridine at a temperature of preferably about 20°-80° C.If pyridine and 4-dimethylaminopyridine are used together as tertiaryamines, the esterification can be performed with low carboxylic acidradicals, preferably at about room temperature and with highercarboxylic acids, preferably at about 40°-80° C. As an example, thereaction with acetic acid or acetic anhydride in the presence of strongacids, such as, for example, trifluoroacetic acid, perchloric acid orp-toluenesulfonic acid, at room temperature or somewhat elevatedtemperature can also be mentioned.

The syntheses of the two possible semi-esters take place by partialesterification or partial saponification:

a) Starting from 3,17β-dihydroxy compounds, the 3-acyloxy-17β-hydroxycompounds can be obtained by selective esterification of the phenolichydroxy group. The reactions are achieved by reacting the correspondingacid anhydride in the presence of a heterocyclic nitrogen aromaticcompound, preferably pyridine. Suitable reaction temperatures are, forexample, about room temperature to boiling temperature of the reactionmixture. Selective esterification of the 3-hydroxy group can also becontrolled by the amount of esterification reagent supplied.

b) Starting from 3,17β-diacyloxy compounds, the 3-hydroxy-17α-acyloxycompounds can be obtained by selective saponification of the phenolicacyloxy group. Synthesis takes place by reaction with an alkalicarbonate or alkaline-earth carbonate, preferably potassium carbonate orcalcium carbonate, in aqueous-methanolic solution. The reactiontemperature can be, for example, room temperature to boiling temperatureof the reaction mixture.

Production of the compounds according to the invention is represented inthe diagram Below, from which the variation of the stereochemistry oncarbon atom 15 can also be seen.

For this purpose, the process described for the production of3-methoxy-15β-methyl-estra-1,3,5(10)-trien-17-one (R. V. Coombs, U.S.Pat. No. 3,766,224; Chem. Abstr. 1974, 80, 27436k) is modified. See thefollowing reaction scheme.

The enolate obtained by adding lithium dialkyl cuprate LiCuR₂ ³ or thecorresponding alkylmagnesium halide (alkyl=R³, halide=Br, I) undercopper(I) catalysis (for example, CuI, CuCN) to3-methoxy-estra-1,3,5(10),15-tetraene-17-one (compound 1), is convertedin situ by adding trimethylchlorosilane to the corresponding silylenolether, which is reacted - optionally without further purification--withpalladium acetate in the sense of a Tsuji dehydrogenation (J. Tsuji etal., Chem. Letters 1133, 1984) to3-methoxy-15-alkyl-estra-1,3,5(10),15-tetraene (see compound 3, 7 or10). By addition of the lithium dialkyl cuprate LiCuR⁴ ₂ or of thecorresponding alkylmagnesium halide (alkyl=R⁴, halide=Br, I) undercopper(I) catalysis (for example, CuI, CuCN) to unsaturated ketone (seecompound 3, 7 or 10), the 15,15-dialkyl-substituted compound (seecompound 4, 5, 8 or 11) is obtained, which is converted by reduction ofthe C-17-carbonyl group according to standard processes to 17β-hydroxycompound (see compound 12, 13, 14 or 15), an initial compound of generalformula II.

By using the corresponding dialkyl lithium cuprates, radicals R³ and R⁴can be varied as desired within the scope of general formula I and bythe analogous course of action for the production of compound 12, 13, 14or 15, the initial compounds of general formula II required forsynthesis of all compounds of general formula I are available.

While the above discussion describes preparation of 3-methoxy compoundsof formula II, the other 3-alkoxy compounds of formula II can beprepared by using the appropriate higher 3-alkoxy homologues of compound1 as the starting material. See U.S. Pat. No. 3,766,224.

If R³ and R⁴ are to be different, the stereochemistry on carbon atom 15can be controlled by the sequence of the alkylation steps. Group R³, thefirst of the two groups added to the C15 position, is located in thefinal end product in α-position.

    ______________________________________                                         ##STR5##                                                                      ##STR6##                                                                      ##STR7##                                                                      ##STR8##                                                                      ##STR9##                                                                     ______________________________________                                        4          R.sup.3, R.sup.4 Me                                                                          12    16                                            5          R.sup.3, Me, R.sup.4 Et                                                                      13    17                                            8          R.sup.3 Et, R.sup.4 Me                                                                       14    18                                            11         R.sup.3 Pr, R.sup.4 Me                                                                       15    19                                            ______________________________________                                    

The 17β-hydroxy compounds of general formula II and the 17-ketocompounds passed through for their synthesis are novel and--takentogether as initial compounds of general formula IIa--also belong to theobject of this invention. ##STR10## wherein

R^(1') is a straight-chain alkyl having 1-10 carbon atoms or abranched-chain alkyl group having 3-10 carbon atoms;

R³ and R⁴, independently of one another, are each a straight-chain alkylhaving 1-10 carbon atoms or a branched-chain alkyl having 3-10 carbonatoms; and

Z is an α-hydrogen atom and a β-hydroxy group or a keto-oxygen atom.

Without further elaboration, it is believed that one skilled in the artcan, using the preceding description, utilize the present invention toits fullest extent. The following preferred specific embodiments are,therefore, to be construed as merely illustrative, and not limitative ofthe remainder of the disclosure in any way whatsoever.

In the foregoing and in the following examples, all temperatures are setforth uncorrected in degrees Celsius and unless otherwise indicated, allparts and percentages are by weight.

The entire disclosure of all applications, patents and publications,cited above, and of corresponding German application P 43 26 240.6,filed Aug. 2, 1993, are hereby incorporated by reference.

EXAMPLES

The following examples are used for a more detailed explanation of theinvention:

Example 1 3-Methoxy-15β-methylestra-1,3,5(10) -trien-17-one (2)

Lithium dimethylcuprate (0.63 mmol) in dry diethyl ether (1 ml)[prepared from copper(I) iodide (120 mg; 0.63 mmol) and methyl lithium(0.75 ml; 1.6M; 1.20 mmol)] was cooled to -78° C. Triethylamine (0.1 ml;0.8 mmol) and chlorotrimethylsilane (0.1 ml; 0.78 mmol) were added,followed by the Δ¹⁵ -17-ketone (1) (84 mg; 0.30 mmol) in drytetrahydrofuran (4 ml). After 5 min., saturated aqueous ammoniumchloride and 1M hydrochloric acid were added. The reaction mixture wasstirred at 20° C. for 15 min. The residue upon work-up (ethyl acetate)(72 mg) was chromatographed on silica gel (6 g), and eluting with ethylacetate-toluene (1:4) gives 3-methoxy-15β-methylestra-1,3,5(10)-trien-17-one (2) (65 mg; 92%) , m.p. 127°-129° C. (fromacetone-methanol) (lit.,¹ m.p. 122°-124° C.); [α]_(D) +74° (c 1.0);υ_(max) 1725 cm⁻¹ (CO); δ_(H) 1.07 (3H, s, 13β-Me); 1.16 (3H, d, J 7.4Hz, 15β-Me), 2.91 (2H, m, 6-H₂), 3.79 (3H, s, 3-OMe), 6.69 (1H, d, J 2.7Hz, 4-H), 6.73 (1H, dd, J 8.6 and 2.7 Hz, 2-H), and 7.21 (1H, d, J 8.6Hz, 1-H); δ_(c) 17.0 (15-Me), 17.9 (C-18), 25.6 (C-15), 26.8 (C-11),27.7 (C-7), 29.5 (C-8), 34.1 (C-16), 35.9 (C-12), 44.5 (C-6), 44.8(C-9), 47.5 (C-13), 55.2 (3-OMe), 111.4 (C-2), 113.9 (C-4), 126.0 (C-1),132.5 (C-10), 137.8 (C-5), 157.7 (C-3), and 221.3 (C-17) (Found: C,80.7; H, 8.6%; M⁺, 298. C₂₀ H₂₆ O₂ requires C, 80.5; H, 8.8%; M, 298).

3-Methoxy-15-methylestra-1,3,5(10),15-tetraen-17-one (3)

(a) A solution of lithium diisopropylamide (5.28 mmol) in drytetrahydrofuran (4 ml) [prepared at 0° C. from diisopropylamine (1.5 ml;10.58 mmol) in dry tetrahydrofuran (4 ml) and butyl lithium (3.3 ml;1.6M; 5.28 mmol)] was cooled to -78° C. and the 15β-methyl-17-ketone (2)(315 mg; 1.05 mmol) in dry tetrahydrofuran (5 ml) was slowly added.Stirring at -78° C. was maintained for 30 min. Chlorotrimethylsilane(1.4 ml; 11.0 mmol) was added and the mixture was allowed to warm to 20°C. After 15 min., the flask was re-cooled to 0° C. and saturated aqueousammonium chloride was added. The residue upon work-up (ethyl acetate)(385 mg) was dissolved in acetonitrile (10 ml). Palladium(II) acetate(233 mg; 1.04 mmol) was added and the mixture was stirred at refluxingtemperature for 15 min. The reaction mixture was cooled to 20° C.,filtered and concentrated to give a dark crystalline product (484 mg).Chromatography on silica gel (24 g), with ethyl acetate-toluene (1:19)as eluent gave 3-methoxy-15-methylestra-1,3,5(10),15-tetraen-17-one (3)(267 mg; 86% from 2), m.p. 156°-158° C. (from ethyl acetate-methanol);[α]_(D) -17° (c 1.0); υ_(max) 1688 cm⁻¹ (CO); δ_(H) 1.11 (3H, s,13β-Me), 2.25 (3H, s, 15-Me), 2.94 (2H, m, 6-H₂), 3.79 (3H, s, 3-OMe),5.77 br (1H, s, 16-H), 6.66 (1H, d, J 2.5 Hz, 4-H), 6.75 (1H, dd, J 8.6and 2.5 Hz, 2-H), and 7.23 (1H, d, J 8.6 Hz, 1-H); δ_(C) 20.9 (C-18),21.5 (15-Me), 25.6 (C-11), 27.7 (C-7), 29.2 (C-9), 29.3 (C-8), 36.8(C-12), 45.2 (C-6), 52.6 (C-13), 55.2 (3-OMe), 57.3 (C-14), 111.5 (C-2),113.6 (C-4), 126.1 (C-1), 128.7 (C-16), 132.0 (C-10), 137.3 (C-5), 157.7(C-3), 175.2 (C-15), and 212.1 (C-17) (Found: C, 81.3, H, 8.15%; M⁺,296. C₂₀ H₂₄ O₂ requires C, 81.0; H, 8.2%; M, 296).

(b) Lithium dimethylcuprate (0.79 mmol) in dry diethyl ether (1 ml) wasprepared as described previously. The reagent was cooled to -78° C.,triethylamine (0.1 ml; 0.8 mmol) and chlorotrimethylsilane (0.1 ml; 0.78mmol) were added, followed by the Δ¹⁵ -17-ketone (1) (106 mg; 0.37 mmol)in dry tetrahydrofuran (4 ml). After 5 min., saturated aqueous ammoniumchloride was added. The residue upon work-up (ethyl acetate) comprised acolorless oil (109 mg). This product was treated under similarconditions of dehydrosilylation as detailed above [66 mg palladium(II)acetate in 5 ml acetonitrile], to yield the 15-methyl-Δ¹⁵ -17-ketone (3)(93 mg; 85% from 1).

3-Methoxy-15,15-dimethylestra-1,3,5(10)-trien-17-one (4)

To a solution of lithium dimethylcuprate (0.79 mmol) in dry diethylether (2 ml) [conventionally prepared at 0° C. from copper(I) iodide(150 mg; 0.79 mmol) and methyl lithium (1.3 ml; 1.6M; 2.08 mmol)] at-78° C., boron trifluoride-diethyl ether complex (0.1 ml; 0.80 mmol) wasadded, followed by the 15-methyl-Δ¹⁵ -17-ketone (3) (163 mg; 0.55 mmol)in dry tetrahydrofuran (2 ml). After 30 min., saturated aqueous ammoniumchloride was added. The standard work-up (ethyl acetate) gave acrystalline residue, chromatography of which on silica gel (5 g),eluting with ethyl acetate-toluene (1:19) gave the 15,15-dimethylketone(4) (146 mg; 70%), m.p. 145°-148° C. (from ethyl acetate-methanol);[α]_(D) +75° (c 1.0); υ_(max) 1727 cm⁻¹ (CO); δ_(H) 1.10 (3H, s,13β-Me), 1.28 and 1.29 (each 3H, s, 15α- and 15β-Me), 1.84 (1H, d, J10.9 Hz, 14α-H), 2.09 and 2.61 (each 1H, d, J 19.4 Hz, 16α- and 16β-H),2.93 (2H, m, 6-H₂), 3.78 (3H, s, 3-OMe), 6.63 (1H, d, J 2.7 Hz, 4-H),6.70 (1H, dd, J 8.6 and 2.7 Hz, 2-H), and 7.21 (1H, d, J 8.6 Hz, 1-H);ac 17.8 (C-18), 24.5 (15-Me), 26.0 (C-11), 28.2 (C-7), 29.8 (C-6), 34.2(C-12), 34.6 (15-Me), 35.5 (C-15), 37.5 (C-8), 44.9 (C-9), 50.2 (C-13),53.6 (C-16), 55.2 (3-OMe), 58.4 (C-14), 111.6 (C-2), 113.6 (C-4), 126.4(C-1), 132.2 (C-10), 137.4 (C-5), 157.6 (C-3), and 221.4 (C-17) (Found:C, 80.5; H, 8.8%; M⁺, 312. C₂₁ H₂₈ O₂ requires C, 80.7; H, 9.0%; M,312).

15β-Ethyl-3-methoxy-15α-methylestra-1,3,5(10)-trien-17-one (5)

A solution of ethylmagnesium iodide (2.5 mmol) in dry diethyl ether (2ml) [prepared at 20° C. from magnesium (60 mg; 2.5 mmol) and ethyliodide (0.2 ml; 2.5 mmol)] was cooled to 0° C., copper(I) iodide (47 mg;0.25 mmol) was added, and the mixture was stirred for 5 min. A solutionof the 15-methyl-Δ¹⁵ -17-ketone (3) (148 mg; 0.5 mmol) in drytetrahydrofuran (2 ml) was added. The reaction mixture was stirred at20° C. for 15 min. Saturated aqueous ammonium chloride and aqueousammonia were added, and the residue upon work-up (ethyl acetate) (150mg; 92%) was crystallized from diisopropyl ether to give15β-ethyl-3-methoxy-15α-methylestra-1,3,5(10)-trien-17-one (5) (135 mg),m.p. 104°-107° C. (from diisopropyl ether-methanol) [α]_(D) +90° (c1.0); υ_(max) 1724 cm⁻¹ ; δ_(H) 0.94 (3H, t, J 7.6 Hz, 15β-CH₂ CH₃),1.09 (3H, s, 13β-Me), 1.22 (3H, s, 15α-Me), 1.63 and 1.76 (each 1H,degen. dq., J 15.2 and 3×7.6, 15β-CH₂ CH₃), 1.87 and 2.80 (each 1H, d, J19.3 Hz, 16α- and 16β-H), 2.91 (2H, m, 6-H₂), 3.78 (3H, s, 3-OMe), 6.64(1H, d, J 2.8 Hz, 4-H), 6.71 (1H, dd, J 8.7 and 2.8 Hz, 2-H), and 7.21(1H, d, J 8.7 Hz, 1-H); δ_(C) 9.0 (C-15²), 18.3 (C-18), 25.9 (C-15¹),27.4 (C-11), 28.6 (C-7), 29.8 (C-6), 30.3 (C-12), 34.4 (15α-Me), 37.3(C-8), 39.4 (C-15), 45.1 (C-9), 48.9 (C-16), 49.8 (C-13), 55.2 (3-OMe),59.8 (C-14), 111.6 (C-2), 113.6 (C-4), 126.4 (C-1), 132.3 (C-10), 137.4(C-5), 157.6 (C-3), and 220.3 (C-17) (Found: C, 80.9; H, 9.6%; M⁺, 326.C₂₂ H₃₀ O₂ requires C, 80.9; H, 9.3%; M, 326).

15β-ethyl-3 -methoxyestra-1,3,5(10)-trien-17-one (6)

A solution of ethylmagnesium iodide (3.8 mmol) in dry diethyl ether (1ml) [prepared from magnesium (91 mg; 3.8 mmol) and ethyl iodide (0.3 ml;3.8 mmol) ] was cooled to 0° C. Copper(I) iodide (71 mg; 0.37 mmol) wasadded. A solution of the enone (1) (200 mg; 0.68 mmol) in drytetrahydrofuran (5 ml) was slowly added, and stirring was maintained at20° C. for 10 min. The mixture was cooled to 0° C., and saturatedaqueous ammonium chloride was added. The residue upon work-up (ethylacetate) (207 mg; 93%) was recrystallized to give15β-ethyl-3-methoxyestra-1,3,5(10)-trien-17-one (6) (198 mg), m.p.125°-129° C. (from chloroform-methanol); [α]_(D) +85° (c 0.95); υ_(max)1727 cm⁻¹ (CO); δ_(H) 0.95 (3H, t, J 7.5 Hz, 15β-CH₂ CH₃), 1.02 (3H, s,13β-Me), 1.34 and 1.65 (each 2H, m, 15β-CH₂ CH₃), 1.90 (1H, dd, J 9.3and 2.7 Hz, 14α-H), 2.39 (2H, m, 16α-and 16β-H), 2.92 (2H, m, 6-H₂),3.79 (3H, s, 3-OMe), 6.66 (1H, d, J 2.9 Hz, 4-H), 6.72 (1H, dd, J 8.4and 2.9 Hz, 2-H), and 7.20 (1H, d, J 8.4 Hz, 1-H); δ_(C) 13.9 (C-15²),17.8 (C-18), 23.8 (C-15¹), 25.6 (C-11), 26.8 (C-7), 29.5 (C-6), 34.0(C-12), 36.0 (C-8), 36.5 (C-15), 42.2 (C-9), 44.6 (C-16), 47.1 (C-13),52.9 (C-14), 55.2 (3-OMe), 111.4 (C-2), 113.9 (C-4), 126.0 (C-1), 132.4(C-10), 137.8 (C-5), 157.7 (C-3), and 221.4 (C-17) (Found: C, 80.6; H,8.9%; M⁺, 312. C₂₁ H₂₈ O₂ requires C, 80.7; H, 9.0%; M, 312).

15-Ethyl-3-methoxyestra-1,3,5(10),15-tetraen-17-one (7)

A solution of lithium diisopropylamide (7.8 mmol) in dry tetrahydrofuran(3 ml) [prepared at 0° C. from diisopropylamine (2.2 ml; 15.8 mmol) intetrahydrofuran (3 ml) and butyl lithium (4.9 ml; 1.6M; 7.8 mmol)] wascooled to -78° C. A solution of the 15β-ethyl ketone (6) (495 mg; 1.58mmol) in dry tetrahydrofuran (12 ml) was slowly added. After 30 min. at-78° C., chlorotrimethylsilane (2.5 ml; 19.7 mmol) was added andstirring was maintained at 0° C. for 15 min. Saturated aqueous ammoniumchloride was added. The residue upon work-up (ethyl acetate) (577 mg)was dissolved in dry acetonitrile (20 ml). Palladium(II) acetate (340mg; 1.51 mmol) was added and the solution was heated to refluxingtemperature for 20 min. The solution was cooled to 20° C., filtered, andevaporated. Chromatography of the residue (470 mg) on silica gel (25 g)and eluting with ethyl acetate (1:19) gave15-ethyl-3-methoxyestra-1,3,5(10),15-tetraen-17-one (7) (419 mg; 85%from 6), m.p. 103°-106° C. (from chloroform-methanol); [α]_(D) 14° (c0.9); υ_(max) 1689 cm⁻¹ ; δ_(H) 1.11 (3H, s, 13β-Me), 1.20 (3H, t, J 7.6Hz, 15-CH₂ CH₃), 2.40 (2H, m, 15-CH₂ CH₃), 3.78 (3H, s, 3-OMe), 5.79 br(1H, s, 16-H), 6.64 (1H, d, J 2.8 Hz, 4-H), 6.73 (1H, dd, J 8.3 and 2.8Hz, 2-H), and 7.22 (1H, d, J 8.3 Hz, 1-H); δ_(C) 11.6 (C-15²), 21.5(C-18), 25.6 (C-11), 27.3 (C-7), 28.0 (C-12), 29.2 (C-15¹), 29.4 (C-6),37.0 (C-8), 45.3 (C-9), 52.6 (C-13), 55.2 (3-OMe), 57.0 (C-12), 111.6(C-2), 113.6 (C-4), 125.7 (C-16), 126.2 (C-1), 132.1 (C-10), 137.3(C-5), 157.5 (C-3), 181.1 (C-15), and 212.2 (C-17) (Found: C, 81.1; H,8.5%; M⁺, 310. C₂₁ H₂₆ O₂ requires C, 81.25; 8.4%; M, 310).

15β-Ethyl-3-methoxy-15β-methylestra-1,3,5(10)-trien-17-one (8)

A solution of methylmagnesium iodide (2.5 mmol) in dry diethyl ether(2.5 ml) [prepared at 20° C. from magnesium (60 mg; 2.5 mmol) and methyliodide (0.16 ml; 2.5 mmol)] was cooled to 0° C. Copper(I) iodide (46 mg;0.24 mmol) was added. After 5 min. at 0° C., a solution of the15-ethyl-Δ¹⁵ -17-ketone (7) (150 mg; 0.48 mmol) in dry tetrahydrofuran(3 ml) was added. The mixture was stirred at 20° C. for 15 min.Saturated aqueous ammonium chloride and aqueous ammonia were added andthe residue upon work-up (ethyl acetate) (150 mg; 96%) was crystallizedfrom chloroform to give the 5α-ethyl-3-methoxy-15β-methylestra-1,3,5(10)-trien-17-one (8) (127 mg; 81%).; m.p. 110°-113° C. (fromchloroform-methanol); [α]_(D) +90° (c 1.0); υ_(max) 1724 cm⁻¹ (CO);δ_(H) 0.89 (3H, t, J 7.4 Hz, 15α-CH₂ CH₃), 1.12 (3H, s, 13β-Me), 1.25(3H, s, 15β-Me), 1.36 and 1.76 (each 2H, degen. dq, J 14.8 and 3×7.4 Hz,15α-CH₂ CH₃), 2.18 and 2.44 (each 1H, d, J 19.4 Hz, 16α- and 16β-H),2.88 (2H, m, 6-H₂), 3.77 (3H, s, 3-OMe), 6.62 (1H, d, J 2.9 Hz, 4-H),6.71 (1H, dd, J 8.6 and 2.9 Hz, 2-H), and 7.20 (1H, d, J 8.6 Hz, 1-H);δ_(C) 9.4 (C-15²), 18.2 (C-18), 21.8 (C-15¹), 26.1 (C-11), 28.3 (C-7),29.9 (C-6), 34.2 (C-12), 37.5 (C-8), 38.1 (15β-Me), 38.9 (C-15), 44.9(C-9), 49.8 (C-16), 50.0 (C-13), 55.2 (3-OMe), 56.6 (C-14), 111.6 (C-2),113.6 (C-4), 126.5 (C-1), 132.2 (C-10), 137.4 (C-5), 157.6 (C-3), and220.4 (C-17) (Found: C, 81.2; H, 9.5%; M⁺, 326. C₂₂ H₃₀ O₂ requires C,80.9; 9.3%; M, 326).

15β- Isopropyl-3-methoxyestra-1,3,5(10)-trien-17-one (9)

Copper(I) iodide-dimethyl sulfide (107 mg; 0.42 mmol) andhexamethylphosphoric triamide (1.1 ml; 6.3 mmol) were added to asolution of isopropylmagnesium bromide (4.25 mmol) [prepared at 0° C.from magnesium (102 mg; 4.25 mmol) and isopropyl bromide (0.4 ml; 4.26mmol)] in dry diethyl ether (5 ml) at 0° C. After 5 min. at thistemperature, a solution of the enone (1) (200 mg; 0.71 mmol) andchlorotrimethylsilane (0.8 ml; 6.30 mmol) in dry tetrahydrofuran wasslowly added. The mixture was stirred at 0° C. for 20 min. Saturatedaqueous ammonium chloride and aqueous ammonia were added. The residueupon work-up (ethyl acetate) (205 mg) was chromatographed on silica gel(20 g), and eluting in ethyl acetate-toluene (1:49) gives15β-isopropyl-3-methoxyestra-1,3,5(10)-trien-17-one (9) (201 mg; 87%),m.p. 104°-108° C. (from diisopropyl ether); [α]_(D) +106° (c 1.0);υ_(max) 1724 cm⁻¹ (CO); δ_(H) 0.96 and 1.10 (each 3H, d, J 6.4 Hz,15β-CHMe₂), 1.08 (3H, s, 13β-Me), 1.92 (1H, dd, J 9.6 and 3.0 Hz,14α-H), 2.41 (2H, m, 16-H₂), 2.89 (2H, m, 6-H₂), 3.79 (3H, s, 3-OMe),6.66 (1H, d, J 2.8 Hz, 4-H), 6.73 (1H, dd, J 8.4 and 2.8 Hz, 2-H), and7.20 (1H, d, J 8.4 Hz, 1-H); δ_(C) 17.4 (C-18), 21.8 and 24.3(15β-CHMe₂), 25.4 (C-11), 28.2 (C-7), 29.5 (C-6), 32.3 (C-8), 34.8(C-12), 38.0 (c-15), 42.4 (c-9), 45.0 (c-16), 45.5 (c-14), 46.5 (C-13),55.2 (3-OMe), 55.4 (15β-CHMe₂), 111.4 (C-₂), 113.9 (C-4), 126.6 (C-1),132.4 (C-10), 137.9 (C-5), 157.7 (C-3), and 222.8 (C-17) (Found: C,80.5; H, 9.3%; M⁺, 326. C₂₂ H₃₀ O₂ requires C, 80.9; H, 9.3%; M, 326).

15-Isopropyl-3-methoxyestra-1,3,5(10),15-tetraen-17-one (10)

A solution of the 15β-isopropyl ketone (9) (210 mg; 0.64 mmol) in drytetrahydrofuran (10 ml) was added to a solution of lithiumdiisopropylamide (3.2 mmol) [prepared at 0° C. from diisopropylamine(0.9 ml; 6.35 mmol) in tetrahydrofuran (2 ml) and butyl lithium (1.9 ml;3.04 mmol)] at -78° C. After 30 min. at this temperature,chlorotrimethylsilane (1 ml; 7.88 mmol) was added. The mixture wasallowed to warm to 0° C. over 20 min. Saturated aqueous ammoniumchloride was added and the residue upon work-up (ethyl acetate). (242mg) was dissolved in dry acetonitrile (20 ml). Palladium(II) acetate(140 mg; 0.62 mmol) was added and the mixture was heated to refluxingtemperature for 20 min. The solution was cooled to 20° C., filtered andevaporated. The residue (230 mg) was chromatographed on silica gel (23g), and eluting with ethyl acetate-toluene (1:19) gives15-isopropyl-3-methoxyestra-1,3,5(10),15-tetraen-17-one (10) (170 mg;81% from 9), m.p. 113°-116° C. (from chloroform-methanol); [α]_(D) -18°(c 1.0); υ_(max) 1690 cm⁻¹ (CO); δ_(H) 1.10 (3H, s, 13β-Me), 1.16 and1.22 (each 3H, d, J 6.6 Hz, 15-CHMe₂), 2.57 (1H, dd, J 11.2 and 2.7 Hz,14α-H), 2.92 (2H, m, 6-H₂), 3.79 (3H, s, 3-OMe), 5.80 (1H, dd, J 2.7 and1.2 Hz, 16-H), 6.65 (1H, d, J 2.7 Hz, 4-H), 6.74 (1H, dd, J 8.6 and 2.7Hz, 2-H), and 7.24 (1H, d, J 8.6 Hz, 1-H); δ_(C) 21.1 (C-18), 21.6 and21.7 (15-CHMe₂), 25.6 (C-11), 28.1 (C-7), 29.1 (C-6), 29.7 (C-8), 30.8(15-CHMe₂), 37.4 (C-12), 45.4 (C-9), 52.6 (C-13), 55.2 (3-OMe), 56.3(C-14), 111.6 (C-2), 113.6 (C-3), 123.9 (C-16), 126.3 (C-1), 132.2(C-10), 137.2 (C-5), 157.7 (C-3), 185.7 (C-15), and 212.4 (C-17) (Found:C, 81.6; H, 8.9%; M⁺, 324. C₂₂ H₂₈ O₂ requires C, 81.4; H, 8.7%; M,324).

15α-Isopropyl-3-methoxy-15β-methylestra-1,3,5(10)-trien-17-one (11)

A solution of lithium dimethyl cuprate (0.61 mmol) in dry diethyl ether(1.5 ml) [prepared at 0° C. from copper(I) iodide (118 mg; 0.61 mmol)and methyl lithium (0.8 ml; 1.6M; 1.28 mmol)] was cooled to -78° C.Triethylamine (0.1 ml; 0.72 mmol) and chlorotrimethylsilane (0.1 ml;0.79 mmol) were sequentially added. Stirring at -78° C. was maintainedfor 5 min., before a solution of the isopropyl eneone (10) (100 mg; 0.31mmol) in dry tetrahydrofuran (3 ml) was added dropwise. The reaction wasstirred for a further 30 min. at 0° C. Saturated aqueous ammoniumchloride and dilute HCl were added. To allow complete hydrolysis of theenol silyl ether, the mixture was stirred at 20° C. for 15 min. Theresidue upon work-up (ethyl acetate) (97 mg) was chromatographed onsilica gel (10 g), and eluting with ethyl acetate-toluene (1:49) gives15β-isopropyl-3-methoxy-15β-methylestra-1,3,5(10)-trien-17-one (11) (92mg; 86%), m.p. 113°-115° C. (from diisopropyl ether); [α]_(D) +87° (c0.9); υ_(max) 1724 cm⁻¹ (CO); δ_(H) (C₆ D₆), 0.68 (6H, d, J 6.0 Hz,15α-CHMe₂), 0.87 (3H, s, 15β-Me), 0.98 (3H, s, 13β-Me), 1.62 obsc (1H,q, J 6.0 Hz, 15α-CHMe₂), 1.95 and 2.15 (each 1H, d, J 19.1 Hz, 16α- and16β-H), 2.68 (2H, m, 6-H₂), 3.44 (3H, s, 3-OMe), 6.70 (1H, d, J 2.6 Hz,4-H), 6.79 (1H, dd, J 8.8 and 2.6 Hz, 2-H), and 7.09 (1H, d, J 8.8 Hz,1-H); δ_(H) (CDCl₃) 0.87 and 0.89 (each 3H, d, J 6.7 Hz, 15α-CHMe₂),1.13 (3H, s, 13β-Me), 1.32 (3H, s, 15β-Me), 2.23 obsc. (2H, d, J 18.7Hz, 16α- and 16β-H), 2.87 (3H, m, 6-H₂), 3.77 (3H, s, 3-OMe), 6.68 (1H,d, J 2.8 Hz, 4-H), 6.75 (1H, dd, J 8.8 and 2.8 Hz, 2-H), and 7.20 (1H,d, J 8.8 Hz, 1-H); δ_(C) 17.8 (C-18), 18.4 and 18.8 (15α-CHMe₂), 23.0(C-11), 26.1 (C-7), 27.8 (15β-Me), 30.0 (C-8), 34.5 (C-12), 36.9(15α-CHMe₂), 37.7 (C-6), 41.5 (C-15), 44.6 (C-9), 45.0 (C-16), 49.9(C-13), 51.6 (C-14), 55.2 (3-OMe), 111.6 (C-2), 113.6 (C-4), 126.5(C-1), 132.2 (C-10), 137.4 (C-5), 157.6 (C-3), and 220.3 (C-17) (Found:C, 81.2; H, 9.6%; M⁺, 340. C₂₃ H₃₂ O₂ requires C, 81.1; H, 9.5%; M,340).

3-Methoxy-15,15-dimethylestra-1,3,5(10)-trien-17β-ol (12)

Lithium aluminum hydride (30 mg; 0.79 mmol) was added to a solution ofthe dimethyl ketone (4) (50 mg; 0.16 mmol) in dry tetrahydrofuran (2 ml)at 0° C. The mixture was stirred at 0° C. for 5 min. Saturated aqueoussodium hydrogen carbonate was added and the mixture was filtered.Work-up of the filtrate (ethyl acetate) gave3-methoxy-15,15-dimethylestra-1,3,5(10)-trien-17β-ol (12) (43 mg; 85%),m.p. 87°-91° C. (from chloroform-hexane), [α]_(D) +75° (c 1.1); υ_(max)3606 cm⁻¹ (OH); δ_(H) 0.92 (3H, s, 13β-Me), 1.06 (1H, d, J 11.2 Hz,14α-H), 1.11 and 1.14 (each 3H, s, 15α- and 15β-Me), 1.61 and 1.90 (each1H, dd, J 13.0 and 10.2, and 13.0 and 7.9 Hz, 16α- and 16β-H), 2.86 (2H,m, 6-H₂), 3.71 (1H, dd, J 10.2 and 7.9 Hz, 17α-H), 3.77 (3H, s, 3-OMe),6.62 (1H, d, J 2.7 Hz, 4-H), 6.71 (1H, dd, J 8.6 and 2.7 Hz, 2-H), and7.21 (1H, d, J 8.6 Hz, 1-H); δ_(C) 13.5 (C-18), 25.6 (15-Me), 26.1(C-11), 28.5 (C-7), 29.9 (C-6), 35.0 (C-12), 36.2 (C-15), 37.1 (C-8),38.8 (15-Me), 44.9 (C-9), 45.6 (C-13), 50.1 (C-16), 55.2 (3-OMe), 58.1(C-14), 79.8 (C-17), 111.4 (C-2), 113.6 (C-4), 126.3 (C-1), 132.9(C-10), 137.7 (C-5), and 157.5 (C-3) (Found: C, 80.0; H, 9.5%; M⁺, 314.C₂₂ H₃₀ O₂ requires C, 80.2; H, 9.6%; M, 314).

15β-Ethyl-3-methoxy-15β-methylestra-1,3,5(10)-trien-17β-ol (13)

Lithium aluminum hydride (58 mg; 0.31 mmol) was added to a solution ofthe 15β-ethyl-15α-methyl ketone (5) (100 mg; 0.31 mmol ) in drytetrahydrofuran (2 ml) at 0° C. The solution was stirred at 0° C. for 5min. Saturated aqueous ammonium chloride was added and the mixture wasfiltered. Standard work-up of the filtrate gave15β-ethyl-3-methoxy-15α-methylestra-1,3,5(10)-trien-17β-ol (13) (92 mg;90%), as an oil, [α]_(D) +70° (c 1.0); υ_(max) 3604 cm⁻¹ (OH); δ_(H)0.88 (3H, t, J 7.2 Hz, 15β-CH₂ CH₃), 0.90 (3H, s, 15α-Me), 1.10 (3H, s,13β-Me), 1.51 obsc (2H, m, 15α-CH₂ CH₃), 1.73 obsc (2H, m, 16α- and16β-H), 2.84 (2H, m, 6-H₂), 3.74 (1H, dd, J 9.9 and 8.2 Hz, 17α-H), 3.78(3H, s, 3-OMe), 6.63 (1H, d, J 2.8 Hz, 4-H), 6.71 (1H, dd, J 8.4 and 2.8Hz, 2-H), and 7.21 (1H, d, J 8.4 Hz, 1-H); δ_(C) 8.6 (C-15²), 13.9(C-18), 25.9 (C-15¹), 28.6 (C-11), 29.0 (C-7), 29.9 (C-6), 30.3 (C-12),36.8 (C-8), 39.0 (15α-Me), 40.0 (C-15), 45.2 (C-9), 45.5 (C-14), 55.2(3-OMe), 59.6 (C-13), 79.5 (C-16), 80.0 (C-17), 111.4 (C-2), 113.6(C-4), 126.2 (C-1), 133.0 (C-10), 137.7 (C-5), and 157.5 (C-3).

15α-Ethyl-3-methoxy-15β-methylestra-1,3,5(10)-trien-17β-ol (14)

Lithium aluminum hydride (48 mg; 1.26 mmol) was added to a solution ofthe 15α-ethyl-15β-methyl ketone (8) (80 mg; 0.25 mmol) in drytetrahydrofuran at 0° C. Low temperature stirring was maintained for 5min. Saturated aqueous sodium hydrogen carbonate was added and themixture was filtered. Standard work-up of the filtrate (ethyl acetate)gave 15α-ethyl-3-methoxy-15β-methylestra-1,3,5(10) -trien-17β-ol (14)(75 mg; 89%), m.p. 133°-136° C. (from chloroform-methanol); [α]_(D) +67°(c 0.9); υ_(max) 3604 cm⁻¹ (OH); δ_(H) 0.88 (3H, t, J 7.2 Hz, 15α-CH₂CH₃), 0.93 (3H, s, 15β-Me), 1.06 (3H, s, 13β-Me), 1.10 (1H, d, J 11.1Hz, 14α-H), 1.32 obsc (2H, m, 15α-CH₂ CH₃), 1.39 and 2.04 (each 1H, dd,J 13.2 and 10.0, and 13.2 and 7.9 Hz, 16α- and 16β-H), 2.84 (2H, m,6-H₂), 3.60 (1H, dd, J 10.0 and 7.9 Hz, 17α-H), 3.77 (3H, s, 3-OMe),6.61 (1H, d, J 2.9 Hz, 4-H), 6.70 (1H, dd, J 8.6 and 2.9 Hz, 2-H), and7.20 (1H, d, J 8.6 Hz, 1-H); δ_(C) 9.4 (C-15²), 13.9 (C-18), 23.7(C-15¹), 26.1 (C-11), 28.6 (C-7), 29.9 (C-6), 37.1 (C-12), 37.7 (C-8),38.9 (15β-Me), 39.7 (C-15), 45.0 (C-9), 45.6 (C-14), 55.2 (3-OMe), 55.6(C-13), 79.3 (C-16), 80.2 (C-17), 111.4 (C-2), 113.6 (C-4), 126.3 (C-1),133.0 (C-10), 137.7 (C-5), and 157.5 (C-3) (Found: C, 80.0; H, 9.7%; M⁺,328. C₂₂ H₃₂ O.sub. requires C, 80.4; H, 9.8%; M, 328) .

15β-Isopropyl-3-methoxy-15β-methylestra-1,3,5(10)-trien-17β-ol (15)

Lithium aluminum hydride (35 mg; 0.92 mmol) was added to a solution ofthe 15α-isopropyl-15β-methyl ketone (11) (63 mg; 0.19 mmol) in drytetrahydrofuran (4 ml) at 0° C. After 10 min. at this temperature,saturated aqueous sodium hydrogen carbonate was added. The mixture wasfiltered, and the clear solution was given the standard work-up (ethylacetate) to give15α-isopropyl-3-methoxy-15β-methylestra-1,3,5(10)-trien-17.beta.-ol (15)(60 mg; 95%), [α]_(D) +54° (c 1.3); υ_(max) 3604 cm⁻¹ (OH); δ_(H) (200MHz), 0.88 and 0.92 (each 3H, d, J 6.8 Hz, 15α-CHMe₂), 0.96 (3H, s,13β-Me), 1.13 (3H, s, 15β-Me), 1.73 (1H, dd, J 13.4 and 10.2 Hz, 16-H),2.13 (1H, dd, J 13.4 and 7.9 Hz, 16-H), 3.54 (1H, dd, J 10.2 and 7.9 Hz,17α-H), 3.78 (3H, s, 3-OMe), 6.64 (1H, dd, J 2.7 Hz, 4 -H), 6.71 (1H,dd, J 8.5 and 2.7 Hz, 2 -H), and 7.22 (1H, d, J 8.5 Hz, 1-H); δ_(C) 14.1(C-18), 18.2 and 18.6 (15α-CHMe₂), 23.6 (C-11), 26.2 (C-7), 28.5(15β-Me), 29.9 (C-8), 36.6 (C-12), 37.3 (15α-CHMe₂), 39.3 (C-6), 40.7(C-15), 42.7 (C-13), 44.7 (C-9), 45.0 (C-16), 51.8 (C-14), 55.2 (3-OMe),80.8 (C-17), 111.4 (C-2), 113.6 (C-4), 126.3 (C-1), 133.0 (C-10), 137.6(C-5), and 157.7 (C-3) (Found: C, 80.4; H, 9.9%; M⁺, 342. C₂₂ H₃₄ O₂requires C, 80.65; H, 10.0%; M, 342) .

Examples 2-5 3-Demethylation of 15,15-dialkyl-17β-alcohols (12-15)Example 2

Representative Procedure: Diisobutylaluminum hydride (0.5 ml; 1.5M; 0.75mmol) was added to a solution of the 5,15-dimethyl-17β-alcohol (12) indry toluene (5 ml). The solution was heated to refluxing temperature for24 h. The mixture was cooled to 0° C., saturated aqueous ammoniumchloride was added, and the aqueous phase was further acidified withdilute HCl. The standard work-up (ethyl acetate) gave15,15-dimethylestra-1,3,5(10)-triene-3,17β-diol (16) (43 mg; 90%), m.p.167-170 (from ethyl acetate); [α]_(D) +49° (c 1.1 ethanol) (Found; C,79.6; H, 9.3%; M⁺, 300. C₂₀ H₂₈ O₂ requires C, 80.0; H, 9.4%; M, 300).

Example 3 15β-Ethyl-15α-methylestra-1,3,5(10) -triene-3,17β-diol (17)

m.p. 132°-136° C. (from ethyl acetate); [α]_(D) +54° (c 1.0 in ethanol(Found: C, 80.4; H, 9.5%; M⁺, 314. C₂₂ H₃₂ O₂ requires C, 80.2; H, 9.6%;M, 314).

Example 4 15α-Ethyl-15β-methylestra-1,3,5(10)-triene-3,17β-diol (18)

obtained as a foam; [α]_(D) +59° (c 1.0 in ethanol) (Found: C, 79.8; H,9.5%; M⁺, 314. C₂₁ H₃₀ O₂ requires C, 80.2, H, 9.6%; M, 314).

Example 5 15α-iso-Propyl-15β-methylestra-1,3,5(10) -triene-3,17β-diol(19)

m.p. 201°-205° C. (from ethyl acetate); [α]_(D) +71° (c 1.0 intetrahydrofuran) (Found: C, 80.7; H, 9.8%; M⁺, 328. C₂₂ H₃₂ O₂ requiresC, 80.4; H, 9.8%; M, 328).

The preceding examples can be repeated with similar success bysubstituting the generically or specifically described reactants and/oroperating conditions of this invention for those used in the precedingexamples.

From the foregoing description, one skilled in the art can easilyascertain the essential characteristics of this invention, and withoutdeparting from the spirit and scope thereof, can make various changesand modifications of the invention to adapt it to various usages andconditions.

What is claimed is:
 1. A 15,15-dialkyl-steroid compound of formula I##STR11## wherein R¹ and R², independently of one another, are eachhydrogen, a straight-chain alkanoyl having 1-10 carbon atoms, abranched-chain alkanoyl having 3-10 carbon atoms, an alkanoyl having3-30 carbon atoms containing a cycloaliphatic structure of 3-6 carbonring atoms, or a benzoyl group; andR³ and R⁴, independently of oneanother, are each a straight-chain alkyl having 1-10 carbon atoms or abranched-chain alkyl having 3-10 carbon atoms.
 2. A compound accordingto claim 1, wherein R¹ is hydrogen.
 3. A compound according to claim 1,wherein R² is hydrogen.
 4. A compound according to claim 2, wherein R²is hydrogen.
 5. A compound according to claim 1, wherein R³ and R⁴,independently of one another, are each methyl, ethyl, propyl, isopropyl,butyl, isobutyl or tert-butyl.
 6. A compound according to claim 4,wherein R³ and R⁴, independently of one another, are each methyl, ethyl,propyl, isopropyl, butyl, isobutyl or tert-butyl.
 7. A compoundaccording to claim 5, wherein R³ and R⁴ are each methyl.
 8. A compoundaccording to claim 7, wherein said compound is15,15-dimethyl-estra-1,3,5(10)-triene-3,17β-diol.
 9. A compoundaccording to claim 6, wherein said compound is15β-ethyl-15α-methylestra-1,3,5(10)-triene-3,17β-diol,15α-ethyl-15β-methylestra-1,3,5(10)-triene-3,17β-diol, or15α-isopropyl-15β-methylestra-1,3,5(10)-triene-3,17β-diol.
 10. A processfor the production of a compound according to claim 1, wherein acompound of formula II ##STR12## wherein R^(1') is a straight-chainalkyl having 1-10 carbon atoms, a branched-chain alkyl having 3-10carbon atoms; andR³ and R⁴, independently of one another, are each astraight-chain alkyl having 1-10 carbon atoms or a branched-chain alkylhaving 3-10 carbon atoms; is subjected to cleavage of the 3-alkyl ethergroup; and optionally the 3-hydroxy group is esterified and thensubsequently the 17-hydroxy group is optionally esterified, oroptionally the 3- and 17-hydroxy groups are simultaneously esterifiedand the resultant 3,17-diacyloxy compound is optionally selectivelysaponified to form a 3-hydroxy-17-acyloxy compound.
 11. A pharmaceuticalcomposition comprising at least one compound according to claim 1 and apharmaceutically compatible vehicle.
 12. A composition according toclaim 11, wherein said composition contains 0.001-0.05 mg of said atleast one compound.
 13. A composition according to claim 11, whereinsaid composition contains 0.01-0.1 mg of said at least one compound perml.
 14. A composition according to claim 11, wherein said compositioncontains 0.1-10 mg of said at least one compound per ml.
 15. A processfor production of a compound of formula II ##STR13## wherein R^(1') is astraight-chain alkyl having 1-10 carbon atoms, a branched-chain alkylhaving 3-10 carbon atoms; andR³ and R⁴, independently of one another,are each a straight-chain alkyl having 1-10 carbon atoms or abranched-chain alkyl having 3-10 carbon atoms; said processcomprising:reacting a 3-R^(1') O-estra-1,3,5(10),15-tetraene-17-onecompound with LiCuR₂ ³ or an alkyl magnesium halide, wherein alkyl is R³and halide is Br or I, under copper(I) catalysis to obtain 3-R^(1')O-15β-R³ -estra-1,3,5(10)-triene-17-one; converting said 3-R^(1')O-15β-R³ -estra-1,3,5(10)-triene-17-one in situ by addition ofchlorotrimethylsilane and subsequent addition of palladium(II) acetateto obtain 3-R^(1') O-15β-R³ -estra-1,3,5(10),15-tetraene-17-one;reacting said 3-R^(1') O-15β-R³ -estra-1,3,5(10),15-tetraene-17-one withLiCuR₂ ⁴ or alkylmagnesium halide, wherein alkyl is R⁴ and halide is Bror I, under copper(I) catalysis to obtain 3-R^(1') O-15α-R³ -15β-R⁴-estra-1,3,5(10)-triene-17-one; and reducing the C-17-carbonyl of said3-R^(1') O-15α-R³ -15β-R⁴ -estra-1,3,5(10)-triene-17-one to obtain saidcompound of formula II.